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Human herpesvirus 6 (HHV-6) can activate the human immunodeficiency virus (HIV) promoter and 
accelerate cytopathic effects in HIV-infected human T cells. This study examines the regions of the HIV 
promoter required for HHVd transactivation in a heterogeneous population of primary human T lymphocytes 
with or without antigenic stimulation. Two different strains of HHV-6, GS and 229, transactivated the HIV 
promoter. The GS strain transactivated the promoter in both stimulated and resting T cells, while the 229 
strain increased HIV promoter activity only in stimulated T cells. Three DNA clones containing HHV-6(GS) 
genomic fragments transactivated the HIV promoter in cotransfected T cells. A 21.4-kb DNA clone, pZVB70, 
showed the highest transactivating ability, while two other DNA fragments, pZVBlO (6.2 kb) and pZVH14 (8.7 
kb), showed lower activity. One of these clones, pZVH14, activated the HIV promoter construct containing a 
mutation in the NFKB site. However, this mutated NFKB promoter was not transactivated during HHV-6(GS) 
infection or after cotransfection with pZVB70 or pZVB10. These data indicate that the NFKB sites of the HIV 
promoter are essential for its transactivation during HHVd(GS) infection. By increasing HIV promoter 
activity in primary T lymphocytes, HHV-6 may consequently increase HIV replication, leading to an increase 
in the cytopathic effect on coinfected human T cells. 
Human CD4+ T lymphocytes are the primary target of the heterogeneity (5). The prototype strain, HHVd(GS), in- 
human immunodeficiency virus (HIV) (4, 20, 31). Infection fected a number of T-cell lines as well as human B lympho- 
with HIV results in the eventual development of AIDS (9, cytes, glioblastoma cells, and megakaryocytic cells (26). In 
10, 23). HIV replication can be shown in only a small contrast, HHV-6(Z29), isolated from a Zairian AIDS patient, 
Percentage of T cells in viva and seems to persist for long infected phytohemagglutinin-stimulated lymphocytes from 
periods of time in a latent phase (2). Because the virus exists cord blood or from adult peripheral blood but failed to 
in a latent phase, infected individuals may not develop replicate in unstimulated lymphocytes and certain T-cell 
clinical manifestations of AIDS for years after the initial HIV lines (5). Recently, we have grown HHV-6(Z29) in the 
infection (2, 15). The latent HIV virus Can be reactivated by Molt-3 T-cell line, in which HHV-fj(GS) failed to replicate. 
various agents such as antigen, mitogen, or cytokine stirnu- HHV-6 infects many of the same target cells as HIV (26), lation (7,21). A wide range of antigenic stimulation and viral and in vitro, HHVd(GS) can also productively coinfect infections have been demonstrated to activate the HIV 
~ ~ ~ - i ~ f ~ ~ ~ ~ d  CD4+ T cells (6, 24, 26). one study showed promoter in various cell lines (13,22,40). However, it is not that this leads to accelerated cytopathic effects in cornpa,+ 
clear to what extent these events occur in viva, and the son ,it,, HIV or HHV-6 infection alone (26). addition, our 
mechanisms involved are not yet completely understood. previous studies have demonstrated that the HIV long A new lymphotropic human herpesvirus terminal repeat (LTR) is activated in HHV-6-infected T-cell (HHV-61, has recently been isolated from peripheral blood lines (14). Activation of the HIV LTR leads to increased lymphocytes of patients with (35, 39)9 patients HIV gene expression, which ultimately leads to a higher 
with lymphoproliferative disorders (351, and from infants level of virus replication. These observations suggest that 
with exanthem subitum (34, 38). Immunological and molec- 
ular analyses have demonstrated that the new herpesvirus is HHV-6 can act as a cofactor in the development and 
distinct from other human herpesviruses (17, 18,25). HHV-6 in the progression of 
productively infects CD4+ human T cells; however, the Study the activation of by HHV-6 under 
strains show variations in their ability to infect physiologic conditions, we have assessed whether or not 
various T cells and T-cell lines (41). They also differ in HHV-6 infection primary human lymphocytes can 
antigenic properties (41) and exhibit DNA restriction site activate the HIV P~OmOter. Furthermore, the effects of 
specific antigenic stimulation in combination with infection 
by two strains of HHV-6 were examined. Results of the 
* Corresponding author. study indicate that HHV-6 strains GS and 229 can activate 
t Present address: Clinical Laboratories, University of Kansas the promoter in primary human lymphocytes and 
Medical Center, Kansas City, KS 66103. differed in their dependency on antigenic stimulation for 
$. Present address: Universal Biotechnology, Inc., Rockville, MD transactivation. Transactivation by HHV-6(GS) involves the 
20850. NFKB region of the HIV LTR. We have also identified three 
2896 HORVAT ET AL. 
different cloned HHV-6(GS) DNA fragments that transacti- 
vate the HIV promoter after cotransfection into human T 
cells. 
MATERIALS AND METHODS 
DNA and plasmids. The HIV chloramphenical acetyltrans- 
ferase (CAT) plasmid has been described in detail previously 
(19). Briefly, the construct contains both the 3' untranslated 
region and the repeat sequences of the HIV LTR aligned 
with the CAT gene. The -147 CAT plasmid was constructed 
by deleting a fragment of the HIV LTR at the AvaI site as 
described elsewhere (13). The -57 CAT plasmid was kindly 
provided by Joseph Sodroski (Harvard Medical School, 
Boston, Mass.) (33). The HIV LTR plasmid containing the 
mutated NFKB site was kindly provided by Gary Nabel (27). 
BamHI plasmid libraries of the HHV-6 genome were gener- 
ated as described previously (17). 
HHVd viral strains and preparation. The human T-cell 
lines HSB-2 (ATCC CCL120.1 CCRF-HSB-2) and Molt-3 
(ATCC CRL 1552) were grown in RPMI 1640 medium 
supplemented with fetal bovine serum and antibiotics. Two 
strains of HHV-6 were used in this study. HHV-6(GS) was a 
gift from R. C. Gallo, National Cancer Institute, Bethesda, 
Md.; HHV-6(Z29) was a gift from P. Pellet, Centers for 
Disease Control, Atlanta, Ga. HHVd(GS) was grown in 
HSB-2 cells, and HHV-6(Z29) was grown in Molt-3 cells. 
Infected cells were collected 6 to 8 days postinfection when 
more than 80% of the cells were positive for viral antigens in 
an indirect immunofluorescence assay (IFA) by using 
HHV-6 specific monoclonal antibodies (3). These infected 
cells were frozen and thawed twice, and the 50% tissue 
culture infectivity dose was determined by procedures de- 
scribed previously (3, 41) on HSB-2 cells for HHV-6(GS) 
and Molt-3 cells for HHV-6(Z29). 
Human T lymphocytes. Fresh mononuclear cells were 
isolated from the peripheral blood of purified protein deriv- 
ative (PPD)-immune, normal human donors by using Hy- 
paque-Ficoll (13). These cells (lo5 per well) were then 
stimulated for 6 days with tuberculin PPD (5 pllml) in 96-well 
round-bottom plates. Lymphoblasts were separated from 
small mononuclear cells and dead cells by using a 35 to 45% 
Percoll step gradient. The cells collected at the interface 
between 35 and 45% were judged to be >98% lymphoblasts 
by microscopic examination. By immunofluorescence, 85 to 
89% of the cells were judged to be CD3+ (Ortho T3 
antibody). These cells are referred to in this report as T-cell 
lymphoblasts and were used for transfections. 
Transfection and infection of T cells. The T-cell lympho- 
blasts were transfected by a DEAE-dextran method (1). 
Briefly, 1 pg of the appropriate DNA in the presence of 700 
pg of DEAE-dextran per ml was added to T-cell lympho- 
blasts or the T-cell line HSB-2 for 3 h at 37OC. The cells were 
then treated with dimethyl sulfoxide (10%) for exactly 1 min. 
After washing, the cells were placed in fresh RPMI 1640 
medium containing 10% human serum. A portion of the 
transfected T cells was then infected with HHV-6(GS) or 
HHV-6(Z29) at a multiplicity of infection of 0.01 by incubat- 
ing the T-cell pellet for 1 h at 37OC with cell lysates of 
HHVd(GS) or HHV-6(Z29). In certain experiments, HHV- 
6(GS) DNA clones were cotransfected with the HIV pro- 
moter constructs into primary T lymphoblasts or the T-cell 
line HSB-2. The transfected and/or infected T cells (2 x lo4 
per well) were then added to either irradiated, adherent, 
autologous mononuclear cells (lo5 per well) alone or cells 
that had been incubated overnight with tuberculin PPD (5 
pVml) in 96-well flat-bottom plates as described earlier (13). 
These cell populations are referred to as resting transfected 
T cells or stimulated transfected T cells, respectively. Five 
days later, the transfected T cells were collected, washed 
twice with phosphate-buffered saline, counted, and used in 
CAT assays. Since a background level of CAT activity is 
observed in fresh T-cell blasts as a result of antigenic 
stimulation, cells were collected 5 days after transfection in 
order to lower this background level of CAT activity. 
CAT assays. Transfected T cells, collected after 5 days, 
were resuspended in 100 p1 of sonication buffer (0.25 M Tris 
HCI, pH 7.4). The cell number was adjusted to 2 X 106/100 
pI so that the same number of cells was used in each CAT 
assay. Cellular extracts were prepared by a single freeze 
(-70°C)-thaw (37°C) cycle and 1 min of sonication, followed 
by centrifugation to remove cell debris. CAT assays using 
['4C]chloramphenicol and thin-layer chromatography have 
been described in detail previously (12). CAT assays using 
[3H]acetyl coenzyme A ([3H]acetyl-CoA) have been de- 
scribed by Neuman et al. (30). Briefly, 50 p1 of the cell 
lysates, [3H]acetyl-CoA, and chloramphenicol was mixed in 
100 mM Tris HCI, pH 8.0. An organic scintillation cocktail 
(Econofluor; Hewlett-Packard) was layered over this mix- 
ture, and the samples were incubated at 37°C. The samples 
were counted in a beta scintillation counter at hourly inter- 
vals after initiation of the assay. Units of CAT activity in 
each cell lysate were calculated according to a standard 
curve established with a CAT sample (Pharmacia) of known 
enzymatic activity. 
RESULTS 
HHV-6(GS) transactivates the HIV LTR promoter in pri- 
mary human T lymphoblasts. The primary T lymphoblasts 
used in this study have been described previously (13) and 
consist of approximately 85% CD3+, 59% CD4+, and 32% 
CD8+ cells. These lymphoblasts were transfected with the 
HIV CAT construct, containing the HIV promoter, by using 
DEAE-dextran. After transfection, a portion of the T cells 
was infected with HHV-6(GS). Five days after infection with 
HHV-6(GS), 30 to 40% of the cells reacted with HHV-6- 
specific monoclonal antibodies (3) by IFA. This result indi- 
cated that the transfected cells were productively infected by 
HHV-6(GS). None of the uninfected lymphocytes reacted 
with HHV-6-specific monoclonal antibodies, indicating the 
absence of endogenous HHV-6 virus. After 5 days in cul- 
ture, lysates were prepared from the transfected cells and 
CAT activity was measured (Fig. 1). Lysates from trans- 
fected T cells without antigen (PPD) stimulation and without 
HHV-6 infection converted 9% of the chloramphenicol sub- 
strate to its acetylated forms, as shown by thin-layer chro- 
matography (Fig. 1A). This lysate contained a total of 0.12 U 
of CAT activity (Fig. 1B and Table 1). Transfected T-cell 
blasts activated with antigen showed higher CAT activity 
than did unstimulated T cells. Lysates from these cells 
converted 79% of the chloramphenicol to its acetylated 
forms and contained a total of 0.46 U of CAT activity (Fig. 
1C). This represents a fourfold increase in CAT activity after 
antigenic stimulation (Table 1). These experiments confirm 
our previous studies, which showed that antigen activation 
of primary T cells can activate the HIV promoter (13). 
Infection of these transfected T cells with HHV-6(GS) 
resulted in transactivation of the HIV promoter in both 
resting and stimulated T cells (Fig. 1A and C). When lysates 
from unstimulated, GS-infected T-cell lymphoblasts were 
tested for CAT activity, there was a conversion of 75% of the 
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FIG. 1. CAT enzymatic activity from primary T-cell lysates. (A) Thin-layer chromatography of [14C]chloramphenicol reacted with cell 
lysates from stimulated T cells (PPD+) and resting T cells (PPD-) either infected with HHV-6 (+) or uninfected (-). (B) Standard curve of 
CAT enzymatic activity obtained by using a rapid method that utilizes [3H]acetyl-CoA. This standard curve is used to calculate the amount 
of CAT activity in cell lysates. As little as 0.01 U of enzymatic activity can be detected per lysate. (C) CAT activity measured in T-cell lysates 
by the rapid method. 
substrate, corresponding to 0.64 U of CAT activity, while 
lysates from activated, infected T cells showed a 99% 
conversion of the substrate and 2.61 U of CAT activity (Fig. 
1A and Table 1). These values represent 5- and 22-fold 
increases in CAT activity without and with antigenic stimu- 
lation, respectively. Since CAT assays with [3H]acetyl-CoA 
TABLE 1. Evidence that the enhancer region of the HIV LTR is 
required for HHV-qGS) transactivationa 
CAT activity (total U in cell lysate) 
Promoter $:! Uninfected cells HHV-&infected cells 
- + - + 
HIV CAT 1 0.12 0.45 (4)' 0.78 (7) 3.04 (25) 
2 0.12 0.45 (4) 0.64 (5) 2.61 (22) 
-147 CAT 1 0.24 1.11 (5) 2.97 (12) 3.84 (16) 
2 0.19 1.08 (6) 2.08 (11) 3.24 (17) 
3 0.16 0.31 (2) 1.49 (9) 2.32 (15) 
-57 CAT 1 <0.01 <0.01 0.05 0.05 
2 <0.01 cO.01 0.03 0.04 
Mutant NFKB- 2 <0.01 <0.01 <0.01 <0.01 
CAT 
3 <0.01 <0.01 <0.01 <0.01 
" Various promoters were transfected into primary T cells by using DEAE- 
dextran. The transfected cells were either cultured directly with autologous, 
irradiated mononuclear cells or infected with HHV-6(GS) and then added to 
feeder cells. Antigen was then added to appropriate cultures. Cells were 
incubated for 5 days, collected, and lysed, and CAT activity was measured. 
Transfected cells were infected with HHV-6(GS) at multiplicity of infection of 
0.01. Some cell cultures were given the antigen PPD (+), while others were 
given medium (-). 
Cells from at least two different donors were transfected with each 
promoter. Cells from each donor were transfected twice. 
Values in parentheses represent the increase in CAT activity based on the 
enzymatic activity found in noninfected, resting T cells. 
are more quantitative and convenient (30), subsequent cell 
lysates were all measured by this rapid method. 
These data show that infection of primary T lymphoblasts 
with HHVd(GS) activates the HIV promoter in both resting 
and stimulated primary T cells. Although the activation in 
resting cells is not as pronounced (5- to 7-fold) as in 
antigen-activated T cells (22- to 25-fold), the data clearly 
demonstrate that HHVd(GS) can infect unstimulated pri- 
mary T cells and will activate the HIV promoter, which 
otherwise remains quiescent. Although activation of resting, 
primary T cells by HHV-6 may have also contributed to the 
low level of transactivation of the HIV promoter, this alone 
cannot account for all of the transactivation activity ob- 
served. 
Transactivation of the HIV promoter in antigen-activated 
primary human T lymphocytes by HHV-6(Z29). Soon after 
the GS strain of HHV-6 was identified, a new variant strain 
of HHV-6 was identified which was designated HHV-qZ29) 
(5). HHV-6(Z29) is related to the GS strain both antigenically 
and genetically (17, 25, 41). Both strains infect human T 
lymphocytes but seem to have a preference for distinct 
subsets. These subsets are still not clearly defined. The 229 
strain can effectively infect the Molt3 T-cell line but not 
HSB-2, while the GS strain infects HSB-2 but not Molt-3. 
Both HHV-6 strains can infect primary human phtyohemag- 
glutinin-stimulated blasts, but HHV-6(Z29) failed to repli- 
cate in unstimulated peripheral blood lymphocytes (41). In 
this study, primary T lymphoblasts specific for the antigen 
tuberculin PPD were transfected with the HIV CAT con- 
struct and then infected with HHV-qZ29). After 6 days, the 
cells were collected and tested for infection with HHV- 
6(Z29) by IFA using cross-reactive HHV-qGS) monoclonal 
antibodies (41). T lymphocytes stimulated with PPD during 
the HHV-6(Z29) infection had enlarged cells and were pos- 
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A DONOR 2 
='O T (W 
Antigen: - + - +  
HHV-6(Z29): - - + + 
B DONOR 4 
5.0 T (404x) 
Antigen: - + - +  
HHV-6(Z29): - - + + 
FIG. 2. Total CAT activity from resting (-) and stimulated (+) T 
cells either infected with HHV-6(Z29) (+) or left uninfected (-). 
Shown are representative results from two different donors; the 
values in parentheses show the increase in total CAT activity 
compared with the activity of unstimulated T lymphoblasts. The 
total units of CAT activity in unstimulated T cells are 0.09 for donor 
2 and 0.011 for donor 4. 
itive for viral antigens. However, T cells infected with 
HHV-6(Z29) in the absence of antigen stimulation showed 
no viral antigen-positive cells. 
After 6 days of culture, transfected T lymphocytes were 
collected, washed, and lysed, and the CAT activity was 
measured from the cell lysates. The results showed that the 
HIV CAT promoter was activated only in HHV-6(Z29)- 
infected human T lymphocytes that had been stimulated with 
antigen. This was explained by the finding that productive 
infections of T lymphocytes with HHV-6(Z29), as deter- 
mined by IFA with HHV-6-specific antibodies, occurred 
only in cells stimulated by antigen. Unstimulated cells did 
not support viral infection, nor did they demonstrate HIV 
CAT promoter activation (0.09 U of CAT activity in donor 2; 
0.011 U of CAT activity in donor 4). As noted above, in 
primary T cells not infected with HHV-6(Z29), the HIV 
promoter was activated by antigenic stimulation (19-fold in 
donor 2, with 1.75 U of CAT activity; 140-fold in donor 4, 
with 1.54 U of CAT activity) (Fig. 2). When the transfected 
T cells were infected with HHV-6(Z29) in the absence of 
antigen, no increase in CAT activity was observed (0.97-fold 
in donor 2, with 0.087 U of CAT activity; 0.7-fold in donor 4, 
with 0.008 U of CAT activity). However, when the trans- 
fected T cells were infected with HHV-6(Z29) and activated 
with PPD, a 46- to 404-fold increase in total CAT activity and 
... ". 
Spl sites 
I Mutant 
-642 NF kB +80 
I I Intact 
I HID CAT 
+80 
FIG. 3. Schematic diagram of the HIV promoters used in this 
study. -57 CAT contained only one Sp l  site and the TATA box as 
well as the tat target sequences. The -147 CAT plasmid contained 
the NFKB site, all of the Sp l  sites, the TATA box, and the tat target 
region but had lost the negative regulatory region (NEG reg). The 
mutant NFKB promoter had all regulatory regions intact but had two 
regions within the NFKB site changed from GGG to TCT. The intact 
HIV CAT promoter had no sequence changed or deleted. 
3-fold increase in activity over antigenic stimulation alone 
were noted (4.18 U of total CAT activity in donor 2; 4.44 U 
of total CAT activity in donor 4). These data indicate that 
HHV-6(Z29) transactivated the HIV LTR in antigen-stimu- 
lated, primary, human T lymphocytes and that transactiva- 
tion by HHV-6(Z29) requires productive infection of primary 
T lymphocytes. 
Transactivation of the HIV promoter in human T lympho- 
cytes by HHV-6(GS) depends on the presence of a functional 
NFKB enhancer site. Earlier studies on the activation of the 
HIV promoter in primary human T lymphocytes showed that 
activation of the HIV promoter was influenced by the NFKB 
enhancer region as well as an upstream region that exerts 
negative regulation (13). Several different constructs of the 
HIV promoter, described in Fig. 3, were transfected into 
PPD-specific human T lymphoblasts. The HIV promoter 
designated -57 CAT contains one of the Spl  sites as well as 
the TATA site. This promoter has been shown to be active in 
other cell types (COS-7; data not shown), but little or no 
promoter activity has ever been observed in primary T 
lymphocytes (13) (Table 1). The promoter designated -147 
CAT retained the NFKB binding region as well as the three 
Spl sites and the TATA box (Fig. 3). This promoter does not 
have the negative regulatory region, and therefore the CAT 
activity expressed after transfection into primary T lympho- 
blasts is somewhat higher than with the intact promoter 
(Table 1). T lymphoblasts transfected with -147 CAT and 
then infected with HHV-6(GS) consistently showed evi- 
dence of transactivation (9- to 17-fold increase in CAT 
activity). This finding indicates that the negative regulatory 
region is not primarily involved in the increased promoter 
activity due to HHV-6(GS) infection. These results also 
show that the DNA sequences responsible for HHV-6(GS) 
transactivation must be within the -147 to -57 region. To 
further locate the specific promoter region responsible for 
HHV-6 transactivation, the HIV LTR plasmid containing a 
mutated NFKB CAT promoter was transfected into primary 
T lymphocytes. This promoter contained two sequences 
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TABLE 2. Evidence that HHV-6(GS) DNA plasmids can 
transactivate the HIV promoter" B 77 mutant NFkB-CAT 
CAT activity (total U in cell lysate) 
HIV-CAT HIV-CAT + HHVd(GS) plasmid 
- 
Antigenic 
T-cell stimulation Antigenic stimulation 
donor Plasmid 
- GS 870 H14 810 843 - GS 870 H I 4  810 
FIG. 4. Total CAT activity from transfected HSB-2 cells. (A) 
HSB-2 cells were transfected with HIV CAT only ( - )  and then 
infected with HHV-6(GS). Cells were also cotransfected with HIV 
CAT and various HHV-6 cloned DNA fragments: pZVB70 (B70), 
pZVH14 (H14), pZVBlO (BlO), and pZVB43 (B43). (B) HSB-2 cells 
were also transfected with mutant NFKB CAT plasmid. Some of the 
cells were infected with HHV-6(GS), while others were left unin- 
fected (-). A portion of the cells were cotransfected with various 
HHV-6 DNA clones as described above. 
" Plasmids containing HHV-6(GS) DNA were cotransfected with HIV CAT 
into primary T cells. CAT activity was measured after 5 days from cell lysate. 
Antigen activation of transfected cells was as described for Table 1. 
See Table 1. footnote c. 
within the NFKB sites that had been changed from GGG to 
CTC (Fig. 3), changes that in the NFKB site eliminate the 
activation of the HIV promoter by the NFKB protein (27). 
This mutation in the NFKB sites abolished the HIV promoter 
activity induced in primary T lymphoblasts both by antigen 
and by HHVd(GS) infection. Although no CAT activity 
could be detected in the lysates from these cells, IFA 
indicated that the population of T cells transfected with the 
mutant NFKB promoter and infected with HHV-6(GS) con- 
tained enlarged cells highly positive for HHV-6(GS) proteins 
(data not shown). This result showed that the transfected T 
cells were productively infected with HHV-6(GS) and sug- 
gests that HHVd(GS) requires the NFKB region for trans- 
activation of the HIV promoter. 
At least three different DNA segments cloned from the 
HHV-6(GS) genome can transactivate the HIV promoter when 
cotransfected into primary T lymphocytes. The HHV-6(GS) 
genome was digested with the restriction enzyme BamHI or 
HindIII, and the resulting fragments were ligated into the 
Bluescript vector (17). Six different HHV-6(GS) DNA frag- 
ments representing about 40% of the total viral genome and 
varying in length from 3.3 to 21.4 kb (17) were used in these 
studies. Each HHVd(GS) fragment was cotransfected with 
HIV CAT into the primary T-cell populations, and CAT 
activity was measured in cell lysates 5 days later. The largest 
fragment, pZVB70 (21.4 kb), showed a dramatic transacti- 
vating effect on the HIV promoter (Table 2). In the absence 
of antigen, this fragment increased HIV promoter activity 26 
to 101 times over the activity expressed in unstimulated T 
cells. When the cells were stimulated with antigen, there was 
a 77- to 271-fold increase in total CAT activity, which was 6- 
to 42-fold over the antigenic stimulation alone. It was the 
major DNA fragment from HHV-6(GS) that showed this 
level of activity, and as such it was designated a high 
transactivator of the HIV promoter. 
Two other HHV-6(GS) fragments, designated pZVH14 
and pZVB10, marginally transactivated the HIV promoter 
(Table 2) when expressed in the absence of antigen stimula- 
tion. The DNA clone pZVH14 contained a 8.7-kb fragment 
from HHV-6(GS), while clone pZVBlO contained a 6.2-kb 
fragment. Since these HHVd(GS) DNA clones showed only 
low-level activation of HIV CAT in the absence of antigen 
and promoter activity in antigen-stimulated cells increased 
only slightly, we have designated these clones low transac- 
tivators. The highest transactivation was observed when 
cotransfected T lymphocytes were stimulated with antigen, 
suggesting an additive effect of antigenic stimulation and the 
HHVd(GS) gene product(s) on HIV promoter activity. 
Table 2 also shows data for three fragments cloned from 
HHV-6(GS) that failed to transactivate the HIV promoter. 
These DNA clones were designated pZVB9 (11.8-kb frag- 
ment), pZVB43 (8.3-kb fragment), and pZVB15 (3.3-kb 
fragment). From these results, it can be concluded that 
HHV-6 contains at least three different gene segments that 
can transactivate the HIV promoter. 
To confirm the data observed in primary T lymphocytes, 
these fragments were also cotransfected with HIV CAT into 
the human T-cell line HSB-2 (Fig. 4A). As previously 
demonstrated (14), infection of the transfected HSB-2 cells 
with HHV-6(GS) resulted in an increase in CAT activity 
(threefold), indicating that the HIV promoter was also trans- 
activated in a T-cell line. Cotransfection of HHVd(GS) 
DNA clone pZVB70 and HIV CAT resulted in a dramatic 
increase in CAT activity (58-fold; Fig. 4A). Plasmid pZVB70 
transactivated HIV CAT to a much greater extent than did 
HHVd(GS). It was also observed that plasmid pZVH14, 
when cotransfected with HIV CAT into the HSB-2 T-cell 
line, activated promoter activity to a higher level than did 
HHV-6(GS). The CAT activity in these samples increased 
30-fold over the activity of HSB-2 cells transfected with HIV 
CAT alone. This finding suggests that during HHV-6(GS) 
infection, the gene products from these DNA segments are 
under some type of regulation that is lost when the genes are 
cloned into plasmids. Cotransfection of HSB-2 cells with 
two other HHV-6 fragments, pZVBlO and pZVB43, did not 
show any transactivation of HIV CAT. These data confirm 
our observation in primary T lymphocytes, that the gene 
segments contained in plasmids pZVB70 and pZVH14 trans- 
activated the HIV promoter; however, unlike the situation 
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TABLE 3. Transactivation of the mutant NFKB promoter with 
HHV-6(GS) DNA clonesa 
CAT activity (total U) 
Mutant NFKB Mutant NFKB + HHV-6(GS) plasmid 
T-cell Antigen stimulation Antigenic stimulation 
donor Plasmid 
- + - + 
" HHV-6(GS) DNA clones were cotransfected with the mutant NFKB 
promoter (see Fig. 3) into primary T cells. Cells were incubated for 5 days as 
described for Table 1. Total CAT activity was measured in cell lysates. 
See Table 1, footnote c. 
for primary T cells, pZVBlO failed to activate the HIV 
promoter in HSB-2 cells. 
To determine whether mutations in the NFKB site of the 
HIV promoter affected the transactivation by cloned HHV- 
6(GS) DNA fragments, the three transactivating fragments 
were cotransfected into primary T cells with the promoter 
containing the NFKB mutation. The resulting promoter 
activities are shown in Table 3. Mutation in the NFKB site 
completely abolished the ability of the pZVB70 and pZVBlO 
clones to transactivate. However, with the pZVH14 clone, a 
slight but consistent transactivation was observed (four- to 
sevenfold) that was less than the transactivation seen with 
the intact HIV promoter. The transactivation of the mutated 
NFKB promoter by pZVH14 was not dependent on antigenic 
stimulation of the T cells, since it was not enhanced by the 
presence of antigen. Similar results were observed when 
these cloned DNA fragments were cotransfected with the 
mutated NFKB promoter into HSB-2 cells (Fig. 4B). The two 
DNA clones, pZVB70 and pZVB10, failed to transactivate 
the mutated NFKB promoter, but pZVH14 showed slight 
transactivation (8- to 10-fold). This finding confirmed the 
results in primary T lymphocytes. Together, these data 
suggest that the transactivating gene(s) included within the 
pZVH14 clone may not totally depend on an intact NFKB 
site but may also use other target DNA region(s) in the 
promoter. 
DISCUSSION 
Our studies demonstrate that two strains of HHV-6, GS 
and 229, can infect and activate the HIV promoter in 
primary, human T lymphocytes. However, these two strains 
of HHV-6 showed distinct differences in ability to transac- 
tivate the HIV promoter, related to the ability of the two 
strains to productively infect resting T lymphocytes. HHV- 
6(GS) infected both stimulated and unstimulated human T 
cells, while HHV-6(Z29) infected only stimulated T cells. 
This observation confirms the results of Wyatt et al. (41), 
who showed that HHV-6(Z29) failed to replicate in nonacti- 
vated peripheral blood lymphocytes. HHV-6(Z29) was un- 
able to infect resting T cells, and no transactivation of the 
HIV promoter was observed. However, HHVd(GS) trans- 
activated the HIV promoter even in resting T cells. These 
data suggest that active replication of HHV-6(Z29) and 
subsequent production of its gene products are required for 
transactivation of the HIV promoter. It is also possible that 
HHV-6(Z29) requires essential cellular elements that are 
provided by antigenic stimulation of T cells for its replica- 
tion, and thus the activation of the HIV promoter by 229 
may require cellular cooperation. Ensoli et al. (8) have 
previously shown that HHVd(GS) infection of HIV-infected 
T cells increases the steady-state level of HIV mRNA that 
parallels CAT enzymatic activity. It is quite possible that 
similar mechanisms are responsible for the increase in CAT 
enzymatic activity observed here. Studies are currently 
under way to examine the mechanism of action by the cloned 
gene fragments. 
Certain difficulties are inherent in these types of experi- 
ments. We have observed differences in HIV promoter 
activation between different donors and even from the same 
donor when cells were donated at different times (6 months 
later). Without HHV-6 infection or antigenic stimulation, the 
background CAT activity ranged between 0.01 and 0.38 total 
U of enzyme activity. Because the increase in promoter 
activity is based on the background activity between donors 
or experiments, this parameter cannot be used to compare 
promoter activity but must be used to measure transactiva- 
tion within a single experiment. This was not expected, since 
these experiments require many steps of long incubation 
periods. Because of the large number of peripheral blood 
mononuclear cells needed for each experiment (>lo0 x lo6), 
donors were only bled every 6 weeks. However, each 
transfection was done at least twice on two different healthy 
adult human donors. Therefore, when transactivation was 
observed consistently in all experiments, we concluded that 
there was activation of the HIV promoter in these situations. 
A number of experiments were performed to identify the 
region of the HIV promoter required for transactivation by 
HHV-6(GS). In earlier studies, several deletions or muta- 
tions in the HIV promoter were used to determine which 
promoter regions were essential for control of the promoter 
activity during primary in vitro T-cell stimulation (13). These 
altered promoters were also used in this study, and the 
results showed that the NFKB region was essential for 
transactivation during HHV-6(GS) infection. Thus, an HIV 
promoter containing mutated sequences within the NFKB 
region was no longer activated by HHVd(GS) infection. It is 
not known whether HHVd(GS) directly activates the NFKB 
cellular protein or, alternatively, a HHV-6(GS) gene prod- 
uc t (~ )  binds directly to the NFKB region. However, these 
results to indicate that this particular promoter region seems 
to be essential for HHVd(GS) transactivation during an 
active infection. Similar results were observed when the 
human T-cell line HSB-2 was transfected with the mutated 
NFKB promoter and then infected with HHV-6(GS). HHV- 
6(GS) is not unique in using the NFKB site, since it has been 
noted that other herpesviruses, such as herpes simplex virus 
type 1, cytomegalovirus, and Epstein-Barr virus, also act on 
the NFKB region of the HIV promoter (22). 
The genome of HHV-6(GS) has been estimated to be 
about 170 kb in length (17, 18), which should code for more 
than 70 proteins. A number of DNA cloned fragments from 
the GS genome were examined in this study to determine 
whether they code for products that transactivate the HIV 
promoter. Several HHVd(GS) DNA clones, comprising 
about 40% of the viral genome, were individually cotrans- 
fected with HIV CAT into primary human T lymphocytes. 
Three different non-cross-hybridizing DNA clones transac- 
tivated the HIV promoter, and at present it is not known 
whether other HHV-6 DNA fragments are also able to 
transactivate the HIV promoter. The DNA clone showing 
the highest level of transactivation (pZVB70) contained 21.4 
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kb of HHV-6(GS) DNA. It is possible that more than one 
gene product expressed from this plasmid is responsible for 
the high level of transactivating ability of this plasmid. Since 
these fragments were not inserted into a eukaryotic expres- 
sion vector, their expression requires endogenous promoter 
activity. It can thus be inferred from these data that at least 
some of the HHV-6 promoters must be active in both 
stimulated and unstimulated primary T cells. Two other 
plasmids containing HHV-6(GS) fragments also transacti- 
vated the HIV promoter in primary T cells. These plasmids 
were pZVH14, which contained an 8.7-kb viral fragment, 
and pZVB10, which contained a 6.2-kb fragment. To deter- 
mine the nature of the open reading frames present in these 
fragments, the DNA was sequenced (data not shown). From 
this information, several genes have been identified and are 
currently been subcloned and tested for transactivating 
ability on the HIV promoter in human T cells. 
Although the pZVH14 clone was less active than pZVB70, 
it transactivated HIV CAT in the T-cell line HSB-2 and in 
primary T cells. Of interest was the observation that this 
fragment, pZVH14, was unique in transactivating the mutant 
NFKB promoter even in the absence of antigenic stimula- 
tion. No such activity was seen after GS infection of T cells 
or transfection of primary T cells with the two transactivat- 
ing DNA fragments from GS, pZVB70 and pZVB10. These 
data also suggest that the gene products expressed from 
pZVH14 are able to act on regions other than the NFKB site, 
independent of antigenic stimulation. This also implies that 
gene expression from this DNA fragment is possible even 
without overt cellular stimulation. Since transactivation of 
the mutant NFKB was not observed during an actual infec- 
tion with HHV-6(GS), the gene(s) contained within the 
pZVH14 DNA fragment must be under some type of regu- 
latory control. A recent study has shown that the pZVH14 
genomic fragment also has oncogenic properties (32). At 
present it is not known whether the gene product(s) the 
induce transformation in NIH 3T3 cells is the same prod- 
u c t ( ~ )  responsible for transactivation of the HIV promoter. 
The immunodeficiency disease AIDS is a chronic disease 
caused by the human retrovirus HIV. The time from HIV 
infection to the clinical manifestation of AIDS can range 
from 2 months to more than a decade (2, 15, 16). An 
important determinant of the length of this latency period is 
the rate of HIV replication. Factors that accelerate HIV 
replication increase the progression of the disease. After 
HIV infection of human T cells in vitro, the virus undergoes 
a form of latency until activated by mitogens or specific 
antigens (42). In vitro stimulation of T cells increases HIV 
promoter activity (13,40), which can terminate HIV latency. 
Thus, activation of the HIV promoter can be a factor in the 
length of the latency period. On the basis of their ability to 
activate the HIV promoter, other DNA viruses, such as 
herpes simplex virus type 1, cytomegalovirus, Epstein-Barr 
virus (22), papovaviruses ( l l ) ,  adenoviruses (28), and hepa- 
titis B virus (36), have been implicated as possible cofactors 
in AIDS. Recent studies have shown that the herpesvirus 
cytomegalovirus enhances the replication of HIV in coin- 
fected cells (37), and cells productively infected with both 
CMV and HIV have been found in the brains of AIDS 
patients (29). These studies indicate that it is possible for 
DNA viruses, especially herpesviruses, to activate HIV 
even in vivo. 
HHV-6 infects primarily CD4+ human T cells, the same 
cells infected with HIV. Several investigators have shown 
that peripheral blood mononuclear cells can be productively 
coinfected with HHV-6 and HIV (6, 24,26). In fact, many of 
the initial HHV-6 strains were isolated from individuals 
suffering from AIDS (25, 35, 39). Therefore, it seems likely 
that coinfection of human T cells with HHV-6 and HIV 
could accelerate the immunodeficiency disease caused by 
HIV. Ensoli et al. (8) showed that T-cell line HSB-2 could be 
productively coinfected with HHV-6 and HIV, resulting in 
accelerated cell death and increased HIV transcription. In 
the present study, the HIV promoter was activated in 
HHVd-infected, primary human T lymphoblasts. In con- 
trast, recent reports have shown that coinfection of periph- 
eral blood mononuclear cells with HHV-6 and HIV sup- 
pressed HIV replication (6, 24). The differences between 
these studies may be due to the nature of the cells that were 
infected, dosage of virus, and time of infection. In the 
present study, 85 to 89% of the transfected cells were human 
T lymphoblasts, whereas the other studies (6, 24) used 
stimulated peripheral blood mononuclear cells which con- 
tained a variety of cell types. It has been demonstrated that 
HHV-6 infects numerous cell types present in peripheral 
blood mononuclear cells, including monocytes and B cells 
(25, 26, 39). Since the mechanism of HIV inhibition by 
HHV-6 in these studies is not known, it still remains possible 
that H H V d  infection of cell types other than T cells con- 
tributes to suppression of HIV replication through cytokine 
production. 
This study has demonstrated that HHV-6 gene products 
can activate the HIV promoter in primary human T lympho- 
blasts. Therefore, an active HHV-6 infection of human T 
cells can activate an otherwise quiescent HIV promoter. 
This promoter activation can lead to an increased HIV 
replication and consequently enhances T-cell death. In ad- 
dition, the replication of HHV-6 itself is cytopathic for T 
cells, which would start a cycle of increased T-cell death. By 
this proposed mechanism, an active HHV-6 infection would 
accelerate the progression of AIDS. 
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